First proof of bismuth oxide nanoparticles as efficient radiosensitisers on highly radioresistant cancer cells

Stewart, C. N.; Konstantinov, Konstantin; McKinnon, Sally; Guatelli, Susanna; Lerch, Michael L. F; Rosenfeld, Anatoly B.; Tehei, Moeava; Corde, Stéphanie

doi:10.1016/j.ejmp.2016.10.015

Cited by 71 publications

(63 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The other kind of bismuth-based nanoparticles which was investigated as radiosensitizer is bismuth oxide nanoparticles (Bi 2 O 3 ). Results of the studies established the effect of Bi 2 O 3 nanoparticles on radiation enhancement by clonogenic and modeling assays [20][21][22]. In our previous work, we confirmed the suitability of multifunction bismuth ferrite nanoparticles (BiFeO 3 ) as a magnetic local dose enhancement.…”

Section: Introductionsupporting

confidence: 72%

Bismuth-based nanoparticles as radiosensitizer in low and high dose rate brachytherapy

Rajaee

Wang

Zhao

2019

Polish Journal of Medical Physics and Engineering

View full text Add to dashboard Cite

Background: Recently bismuth-based nanoparticles have attracted increasing attention as a dose amplification agent in radiation therapy due to high atomic number, high photoelectric absorption, low cost, and low toxicity. Objectives: This study aims to calculate physical aspects of dose enhancement of bismuth-based nanoparticles in the presence of brachytherapy source by Monte Carlo simulation and an analytical method for low mono-energy. Materials and methods: After simulation and validation brachytherapy sources (Iodine-125 and Ytterbium-169) by Monte Carlo code, bismuth-based nanoparticles (bismuth, bismuth oxide, bismuth sulfide, and bismuth ferrite) were modeled in the sizes of 50 nm and 100 nm for two concentrations of 10 and 20 mg/ml. Dose enhancement factors for the bismuth-based nanoparticles were measured at both brachytherapy sources. Furthermore, the dose amplification was calculated with an analytic method at 30 keV mono-energy. Results: Dose enhancement factor was greatest with pure bismuth nanoparticles, followed by bismuth oxide, bismuth sulfide and bismuth ferrite for both radiation source and simulation methods. The dose amplification for the bismuth-based nanoparticles increased with increasing size and concentration of nanoparticles. Conclusion: The physical aspect dose enhancement of the nanoparticles was shown by Monte Carlo and analytic method. The results have proved bismuth-based nanoparticles deserve further study as a radiosensitizer.

show abstract

Section: Introductionsupporting

confidence: 72%

Bismuth-based nanoparticles as radiosensitizer in low and high dose rate brachytherapy

Rajaee

Wang

Zhao

2019

Polish Journal of Medical Physics and Engineering

View full text Add to dashboard Cite

show abstract

“…Given that a small fraction of photons induce the photoelectric effect upon MV radiation, Bi NMs mediated radiosensitizing is expected with a negligible enhancement ratio, as calculated by Monte Carlo. [ 38 ] The survival curve of cells treated by Bi NPs upon 10 MV radiation showed a dose enhancement ratio of 1.25. [ 38 ] This difference can be justified by processes occurring within the biological tissue followed by ionizing radiation.…”

Section: Classification and Characteristics Of Major Cancer Monotheramentioning

confidence: 99%

“…[ 38 ] The survival curve of cells treated by Bi NPs upon 10 MV radiation showed a dose enhancement ratio of 1.25. [ 38 ] This difference can be justified by processes occurring within the biological tissue followed by ionizing radiation. The chemical, physical, and biological processes are introduced as RT efficiency enhancement pathways ( Figure a), [ 39 ] whereas in the theoretical predictions by Monte Carlo, only the physical phase are involved in the Bi NPS + XRT‐induced sensitivity enhancement ratio (SER).…”

Section: Classification and Characteristics Of Major Cancer Monotheramentioning

confidence: 99%

“…The chemical, physical, and biological processes are introduced as RT efficiency enhancement pathways ( Figure a), [ 39 ] whereas in the theoretical predictions by Monte Carlo, only the physical phase are involved in the Bi NPS + XRT‐induced sensitivity enhancement ratio (SER). [ 38 ] Therefore, Bi‐based NMs are becoming potential radiation sensitizers due to their high X‐ray absorption ability ( Table 2 ).…”

Section: Classification and Characteristics Of Major Cancer Monotheramentioning

confidence: 99%

See 1 more Smart Citation

Bismuth‐Based Nanomaterials: Recent Advances in Tumor Targeting and Synergistic Cancer Therapy Techniques

Badrigilan

Choupani

Khanbabaei

et al. 2020

Adv Healthcare Materials

View full text Add to dashboard Cite

Despite all of the efforts in the field of cancer therapy, the heterogeneous properties of tumor cells induce an insufficient therapeutic outcome when treated with conventional monotherapies, necessitating a shift in cancer treatment from monotherapy to combination therapy for complete cancer treatment. Multifunctional bismuth (Bi)‐based nanomaterials (NMs) with therapeutic functions hold great promise for the fields of cancer diagnosis and therapy based on their low toxicity, X‐ray sensitive capabilities, high atomic number, near‐infrared driven semiconductor properties, and low cost. Herein, a comprehensive review of recent advances in various medicinal aspects of Bi‐based NMs is presented including: evaluation of in‐tumor site accumulation, tumor targeting, and therapeutic performance, as well as the characteristics, benefits, and shortcomings of Bi‐based NM‐mediated major monotherapies. In addition, the cooperative enhancement mechanisms between two or more of these monotherapies are described in detail to address common challenges in cancer therapy, such as multidrug resistance, hypoxia, and metastasis. Finally, this review opens new insights into the design of multimodal synergistic therapies for potential future clinical applications of Bi‐based NMs.

show abstract

“…Bismuth and its complexes are found to have many properties such as antibacterial [13], antiproliferative, antimicrobial [21] and high radiation absorption coefficient that make it suitable as contrast agents in X-ray computed tomography for medical imaging [20]. Bismuth oxide NPs (BiONPs) have been introduced as a radiosensitizer because the presence of bismuth may trigger additional retention, absorption, and scattering of the radiation at the cancer site [22], and thus demonstrated a higher enhancement of the dose, in comparison to other types of NPs [23]. Cytotoxicity effects have been reported in previous literature indicating 50 % of cells inhibition concentration values (IC 50 ) caused by BiONPs on HepG2 liver, NRK-52E kidney, Caco-2 colorectal and A549 lung cell lines [24].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Bismuth Oxide Nanoparticles as Radiosensitizer for Megavoltage Radiotherapy

Sisin¹,

Abidin²,

Amir³

et al. 2019

Int. J. Adv. Sci. Eng. Inf. Technol.

View full text Add to dashboard Cite

Metal-based nanoparticles such as gold, silver, platinum, and bismuth have been widely investigated for radiotherapeutic application. Basic understanding of the cellular interaction of the nanoparticles with the biological materials is crucial to ensure future clinical use. In this study, the cytotoxicity, cellular uptake, and generation of reactive oxygen species (ROS) induced by BiONPs were investigated prior elucidating the feasibility of BiONPs for radiotherapy application using megavoltage photon and electron beams. The BiONPs of diameter sizes 60, 70, 80 and 90 nm at concentrations within a range of 0.5 to 0.00005 mMol/L were tested on MCF-7, MDA-MB-231, and NIH/3T3 cells lines. The cytotoxicity results exhibit minimal cell death constituting less than 20 % of mortality on average. The ROS generation by BiONPs alone is found to be negligible as the ROS levels were slightly lower and higher than 100% of positive control. The increment of cellular nanoparticles uptake from a range of 1.50 % to 34.10 % indicates that BiONPs were internalized and bound to the surface of the cells. Sequencing from the results, 60 nm BiONPs are found to be the most suitable to be applied as a radiosensitizer in radiotherapy. Sensitization enhancement ratio (SER) quantified on MCF-7 cells demonstrated the highest enhancement from the highest concentration of BiONPs with SER of 2.29 and 1.42, for 10 MV photon beam and 6 MeV electron beam, respectively. In contrast to ROS production without radiation, the ROS induced from radiotherapy beams were found to be dose-dependent and play significant roles in radiosensitization effect. In conclusion, BiONPs could improve clinical radiotherapy, and further radiobiological characterization is crucial for future clinical translation.

show abstract

First proof of bismuth oxide nanoparticles as efficient radiosensitisers on highly radioresistant cancer cells

Cited by 71 publications

References 32 publications

Bismuth-based nanoparticles as radiosensitizer in low and high dose rate brachytherapy

Bismuth-based nanoparticles as radiosensitizer in low and high dose rate brachytherapy

Bismuth‐Based Nanomaterials: Recent Advances in Tumor Targeting and Synergistic Cancer Therapy Techniques

Evaluation of Bismuth Oxide Nanoparticles as Radiosensitizer for Megavoltage Radiotherapy

Contact Info

Product

Resources

About